Nipah Virus mAb

About Mapp Biopharmaceutical

Mapp Biopharmaceutical is a private, clinical-stage biotech focused on developing monoclonal antibody countermeasures against deadly viral threats like Nipah, Marburg, and Junín viruses. The company leverages strategic partnerships, notably with BARDA, to advance its pipeline through non-clinical and clinical development. With a mission-driven approach to global health and biodefense, Mapp is progressing multiple candidates, including one now in human trials for Nipah virus, positioning it as a key player in the preparedness and response landscape for emerging infectious diseases.

Therapeutic Areas